Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease
ABSTRACT Background Neurofilament light chain protein (NfL) is a promising biomarker of neurodegeneration. Objectives To determine whether plasma and CSF NfL (1) associate with motor or cognitive status in Parkinson's disease (PD) and (2) predict future motor or cognitive decline in PD. Methods...
Gespeichert in:
| Veröffentlicht in: | Movement disorders Jg. 36; H. 12; S. 2945 - 2950 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Hoboken, USA
John Wiley & Sons, Inc
01.12.2021
Wiley Subscription Services, Inc |
| Schlagworte: | |
| ISSN: | 0885-3185, 1531-8257, 1531-8257 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | ABSTRACT
Background
Neurofilament light chain protein (NfL) is a promising biomarker of neurodegeneration.
Objectives
To determine whether plasma and CSF NfL (1) associate with motor or cognitive status in Parkinson's disease (PD) and (2) predict future motor or cognitive decline in PD.
Methods
Six hundred and fifteen participants with neurodegenerative diseases, including 152 PD and 200 healthy control participants, provided a plasma and/or cerebrospinal fluid (CSF) NfL sample. Diagnostic groups were compared using the Kruskal−Wallis rank test. Within PD, cross‐sectional associations between NfL and Unified Parkinson's Disease Rating Scale Part III (UPDRS‐III) and Mattis Dementia Rating Scale (DRS‐2) scores were assessed by linear regression; longitudinal analyses were performed using linear mixed‐effects models and Cox regression.
Results
Plasma and CSF NfL levels correlated substantially (Spearman r = 0.64, P < 0.001); NfL was highest in neurocognitive disorders. PD participants with high plasma NfL were more likely to develop incident cognitive impairment (HR 5.34, P = 0.005).
Conclusions
Plasma NfL is a useful prognostic biomarker for PD, predicting clinical conversion to mild cognitive impairment or dementia. © 2021 International Parkinson and Movement Disorder Society |
|---|---|
| Bibliographie: | Funding Agencies This research was supported by the National Institutes of Health (NIH) (RO1 NS115139, U19 AG062418, P50 NS053488, P30 AG010124, K23 NS11416, T32 NS061779), and a Biomarkers Across Neurodegenerative Diseases (BAND) grant from The Michael J. Fox Foundation/Alzheimer's Association/Weston Institute. Alice Chen‐Plotkin is additionally supported by the Parker Family Chair. Authors report no disclosures or conflicts of interest relevant to this work. Relevant conflicts of interest/financial disclosures ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 T.F.T.: 1A, 2B, 2C, 3B (1) Research Project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript Preparation: A. Writing of the First Draft, B. Review and Critique. A.S.: 1B, 2C, 3B L.M.S.: 1A, 1B, 1C, 2C, 3A, 3B J.Q.T.: 1B, 2C, 3B T.W.: 1B, 1C, 3B A.S.C.-P.: 1A, 1B, 1C, 2A, 2C, 3A, 3B D.A.W.: 1B, 2C, 3B D.W.: 1B, 2C, 3B M.G.: 1B, 2C, 3B SGML and CITI Use Only DO NOT PRINT S.X.X.: 2A, 2B, 2C, 3B Author Roles W.W.A.: 1A, 1B, 1C, 2B, 2C, 3A, 3B J.S.: 1C, 2B, 2C, 3B D.I.: 1B, 2C, 3B |
| ISSN: | 0885-3185 1531-8257 1531-8257 |
| DOI: | 10.1002/mds.28779 |